175 related articles for article (PubMed ID: 12071533)
1. Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality.
Nishi M; Takeda T; Hatae Y; Hanai J; Fujita K; Ichimiya H; Tanaka T
J Exp Clin Cancer Res; 2002 Mar; 21(1):73-8. PubMed ID: 12071533
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening.
Carlsen NL
Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115
[TBL] [Abstract][Full Text] [Related]
4. Past and future of neuroblastoma screening in Japan.
Sawada T
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397
[TBL] [Abstract][Full Text] [Related]
5. Screening of infants and mortality due to neuroblastoma.
Woods WG; Gao RN; Shuster JJ; Robison LL; Bernstein M; Weitzman S; Bunin G; Levy I; Brossard J; Dougherty G; Tuchman M; Lemieux B
N Engl J Med; 2002 Apr; 346(14):1041-6. PubMed ID: 11932470
[TBL] [Abstract][Full Text] [Related]
6. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].
Sawada T; Nagahara N; Ohi R; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Ohkawa H; Tunoda A
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868
[TBL] [Abstract][Full Text] [Related]
7. Mass screening of neuroblastoma in Sapporo City, Japan.
Nishi M; Miyake H; Takeda T; Kikuchi Y; Hanai J; Yonemori H; Takasugi N
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):327-31. PubMed ID: 1456398
[TBL] [Abstract][Full Text] [Related]
8. Is the mass screening for neuroblastoma ineffective?
Nishi M; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hatae Y; Takeda T
J Exp Clin Cancer Res; 2003 Dec; 22(4):673-6. PubMed ID: 15053313
[TBL] [Abstract][Full Text] [Related]
9. Mass screening for neuroblastoma and mortality in birth cohorts.
Nishi M; Miyake H; Takeda T; Hanai J; Kikuchi Y; Takasugi N
Int J Cancer; 1997 May; 71(4):552-5. PubMed ID: 9178807
[TBL] [Abstract][Full Text] [Related]
10. Effects of mass screening for neuroblastoma and the presumptive natural history of this tumor.
Takeda T; Shimada M; Iizuka S; Takasugi N
Prog Clin Biol Res; 1994; 385():383-8. PubMed ID: 7972235
[TBL] [Abstract][Full Text] [Related]
11. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
12. [The "Lower Saxony/Northern Rhine-Westphalia" Neuroblastoma Screening Project: on the need for epidemiologic comparison].
Berthold F; Sander J; Baillot A; Hunneman DH; Michaelis J
Klin Padiatr; 1992; 204(4):288-92. PubMed ID: 1518267
[TBL] [Abstract][Full Text] [Related]
13. Maturation of mass-screened localized adrenal neuroblastoma.
Iwanaka T; Yamamoto K; Ogawa Y; Arai M; Ito M; Kishimoto H; Hanada R; Imaizumi S
J Pediatr Surg; 2001 Nov; 36(11):1633-6. PubMed ID: 11685689
[TBL] [Abstract][Full Text] [Related]
14. Neuroblastoma screening at one year of age.
Schilling FH; Spix C; Berthold F; Erttmann R; Fehse N; Hero B; Klein G; Sander J; Schwarz K; Treuner J; Zorn U; Michaelis J
N Engl J Med; 2002 Apr; 346(14):1047-53. PubMed ID: 11932471
[TBL] [Abstract][Full Text] [Related]
15. Progression of mean age and mean expected mortality rate by duration of follow up in cohorts with a wide range of age.
Singer RB
J Insur Med; 2006; 38(3):181-91. PubMed ID: 17076138
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastoma screening in Japan: population-based cohort study and future aspects of screening.
Hiyama E
Ann Acad Med Singap; 2008 Dec; 37(12 Suppl):88-4. PubMed ID: 19904462
[TBL] [Abstract][Full Text] [Related]
17. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years.
Wilcken B; Haas M; Joy P; Wiley V; Bowling F; Carpenter K; Christodoulou J; Cowley D; Ellaway C; Fletcher J; Kirk EP; Lewis B; McGill J; Peters H; Pitt J; Ranieri E; Yaplito-Lee J; Boneh A
Pediatrics; 2009 Aug; 124(2):e241-8. PubMed ID: 19620191
[TBL] [Abstract][Full Text] [Related]
18. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan.
Ajiki W; Tsukuma H; Oshima A; Kawa K
Cancer Causes Control; 1998 Dec; 9(6):631-6. PubMed ID: 10189049
[TBL] [Abstract][Full Text] [Related]
19. Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan.
Katanoda K; Hayashi K; Yamamoto K; Sobue T
J Epidemiol; 2009; 19(5):266-70. PubMed ID: 19652443
[TBL] [Abstract][Full Text] [Related]
20. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: A descriptive study.
Shinagawa T; Kitamura T; Katanoda K; Matsuda T; Ito Y; Sobue T
Int J Cancer; 2017 Feb; 140(3):618-625. PubMed ID: 27778323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]